Australia markets closed

Aequus Pharmaceuticals Inc. (AQS.V)

TSXV - TSXV Real-time price. Currency in CAD
Add to watchlist
0.0300+0.0100 (+50.00%)
At close: 03:57PM EDT
Currency in CAD

Valuation measures4

Market cap (intra-day) 3.98M
Enterprise value 9.41M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)18.49
Price/book (mrq)N/A
Enterprise value/revenue 43.72
Enterprise value/EBITDA -2.87

Trading information

Stock price history

Beta (5Y monthly) 0.23
52-week change 3-25.00%
S&P500 52-week change 322.55%
52-week high 30.0550
52-week low 30.0100
50-day moving average 30.0221
200-day moving average 30.0251

Share statistics

Avg vol (3-month) 3164.64k
Avg vol (10-day) 367.01k
Shares outstanding 5132.63M
Implied shares outstanding 6132.63M
Float 8112.79M
% held by insiders 114.68%
% held by institutions 10.00%
Shares short (14 June 2024) 41.44k
Short ratio (14 June 2024) 40
Short % of float (14 June 2024) 4N/A
Short % of shares outstanding (14 June 2024) 40.00%
Shares short (prior month 15 May 2024) 432.53k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,161.72%

Management effectiveness

Return on assets (ttm)-165.20%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)215.2k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-43.00%
Gross profit (ttm)N/A
EBITDA -2.71M
Net income avi to common (ttm)-2.88M
Diluted EPS (ttm)-0.0100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)242.04k
Total cash per share (mrq)0
Total debt (mrq)5.67M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.09
Book value per share (mrq)-0.04

Cash flow statement

Operating cash flow (ttm)-2.55M
Levered free cash flow (ttm)-1.53M